- Quebec public reimbursement
coverage to facilitate and expand medication access for Parkinson's
patients in Quebec
MONTREAL, Feb. 7, 2023
/CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:
VP2) ("Valeo" or the "Company"), a Canadian
pharmaceutical company, today announced that Onstryv® (safinamide)
for the treatment of patients suffering from Parkinson's disease,
is now listed for public reimbursement on the Public Prescription
Drug Insurance Plan of the Quebec
Régie de l'assurance maladie du Québec ("RAMQ"), effective
February 1, 2023.
Onstryv® is approved by Health Canada as an add-on therapy to a
regimen that includes levodopa for the treatment of the signs and
symptoms of idiopathic Parkinson's Disease in patients experiencing
"off" episodes. Onstryvâ is a prescription medication available at
pharmacies across Canada in 50mg
and 100mg tablets.
"Securing public reimbursement coverage is an important
milestone for the commercialization of Onstryv in Quebec", said Steve
Saviuk, Chief Executive Officer "Onstryv reimbursement
coverage by the RAMQ will play a significant role in facilitating
and expanding access to one of the few new treatments for Parkinson
approved in Canada in well over a
decade."
Parkinson's Disease is a progressive neurological disease
involving the loss of dopamine producing neurons in the brain.
While tremors are the best known symptom, Parkinson's Disease also
causes other symptoms including slowed movement, rigid muscles,
impaired posture and balance, speech and writing difficulties. On a
per capita basis, Canada has
amongst the highest incidences of Parkinson's Disease in the world
and the number of patients is expected to grow significantly over
the next thirty years as the median population age increases.
About Onstryv®
(safinamide)
Safinamide, known as Onstryv® in Canada and Xadago® in the rest of the world,
is a chemical entity with a unique mode of action including
selective and reversible MAO-B inhibition. Clinical trials have
established its efficacy in controlling motor symptoms and motor
complications in the short term, maintaining this effect over 2
years. Results from 24 month double-blind controlled studies
suggest that safinamide shows statistically significant effects on
motor fluctuations (ON/OFF time) without increasing the risk of
developing troublesome dyskinesia. Onstryv® is a once-daily dose
and has no diet restrictions due to its high MAO-B/MAO-A
selectivity.
About Valeo Pharma
Valeo Pharma is a Canadian pharmaceutical company dedicated to
the commercialization of innovative prescription products in
Canada with a focus on
Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Headquartered in Kirkland, Quebec
Valeo Pharma has all the necessary capabilities and a complete
infrastructure to register and manage its growing product portfolio
through all stages of commercialization. For more information,
please visit www.valeopharma.com and follow us on LinkedIn and
Twitter.
Forward Looking
Statements
This press release contains forward-looking statements about
Valeo's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate.
SOURCE Valeo Pharma Inc.